|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The presence of either PNPLA3 G/G or TM6SF2*/T identified high-risk genotypes for HCC, which were strongly associated with HCC (64/150 vs. 93/361, p=0.0002).
|
26493626 |
2016 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Among individuals homozygous for the PNPLA3 G allele (n = 115), the frequency of the JAZF1 rs864745 G allele was significantly higher among DM-HCC individuals than DM-non-HCC individuals (OR 3.44, p = 0.0002).
|
26337813 |
2016 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Carriage of the PNPLA3 rs738409 C >G polymorphism is not only associated with greater risk of progressive steatohepatitis and fibrosis but also of HCC.
|
24607626 |
2014 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In particular, the common I148M variant of the PNPLA3 gene influencing hepatic lipid metabolism influences HCC risk independently of its effect on the progression of liver fibrosis.
|
25278690 |
2014 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Modulation of serum adiponectin might be involved in mediating the susceptibility to steatosis, NASH, and hepatocellular carcinoma in carriers of the 148 M PNPLA3 variant without CHC, with potential therapeutic implications.
|
22898488 |
2012 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Recent advances include the identification of PNPLA3 as a modifier of disease outcome across the full spectrum of NAFLD from steatosis to advanced fibrosis and hepatocellular carcinoma; and the discovery of TM6SF2 as a potential "master regulator" of metabolic syndrome outcome, determining not only risk of advanced liver disease, but also cardiovascular disease outcomes.
|
26378644 |
2015 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This study was conducted to determine whether PNPLA3 rs738409 SNPs affect development and prognosis of hepatocellular carcinoma (HCC) in patients with various liver diseases.
|
22869157 |
2013 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Thus, polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with HCC development in Japanese patients with chronic HCV infection.
|
28928439 |
2017 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
In conclusion, we identified liver-specific genes linked to NAFLD pathogenesis, such as pyruvate kinase liver and red blood cell (PKLR), or to HCC pathogenesis, such as PKLR, patatin-like phospholipase domain containing 3 (PNPLA3), and proprotein convertase subtilisin/kexin type 9 (PCSK9), all of which are potential targets for drug development.
|
28827398 |
2017 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
ALT, lipid profile, PNPLA3 variant distribution and HBV viral load did not differ among co-infected patients with or without HCC.
|
25536644 |
2015 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Homozygosity for PNPLA3 148M was associated with reduced survival in the overall series (p = 0.009), and with a higher number of HCC lesions at presentation (p = 0.007) and reduced survival in ALD&NAFLD patients (p = 0.003; median survival 30, 95% c.i.20-39 vs. 45, 95% c.i.
|
24155878 |
2013 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Steatohepatitis was associated with all-cause mortality [Hazard ratio (HR) 3.1, 95%CI: 1.3-7.3, P = 0.006] and HCC (HR 2.8, 95%CI: 0.9-9.2, P = 0.078), but no significant association was observed for PNPLA3.
|
25284145 |
2015 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Recent reports revealed an association between variation in the PNPLA3 gene and alcohol-induced hepatocellular carcinoma among Europeans.
|
24269995 |
2014 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We also explored the possible effect of PNPLA3 genotype on other steatosis-related complications, namely, treatment failure and hepatocellular carcinoma (HCC) development.
|
21319195 |
2011 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In end-stage liver disease patients, we identified ALD to be predominantly affected by the PNPLA3 I148M variant resulting in an increased risk of HCC and reduced transplantation free survival.
|
25273282 |
2014 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study.
|
29089161 |
2018 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Overall, these results suggest that rs738409 exerts a marked influence on hepatocarcinogenesis in patients with cirrhosis of European descent and provide a strong argument for performing further mechanistic studies to better understand the role of PNPLA3 in HCC development.
|
24114809 |
2014 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
These data showed that PNPLA3 and TM6SF2 polymorphisms were independently linked to NBNC-HCC but not HBV- or HCV-HCC in Thai populations.
|
30506232 |
2019 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Carriage of both PNPLA3 rs738409 and TM6SF2 rs58542926 accounts for half of the attributable risk for HCC in this population.
|
29535416 |
2018 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Recently, the common variant p.I148M of the enzyme adiponutrin (PNPLA3) has emerged as a major genetic determinant of hepatic steatosis and nonalcoholic steatohepatitis as well as its pathobiological sequelae fibrosis, cirrhosis, and hepatocellular cancer.
|
24222094 |
2013 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms (such as PNPLA3, TM6SF2 and MBOAT7) are related to the susceptibility to the development of HCC and its progression.
|
31717576 |
2019 |
|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
As expected, overexpression of ATGL in cultured hepatoma (HuH-7) cells depleted the cells of LDs, but unexpectedly, co-expression of PNPLA3(wild type [WT] or 148M) with ATGL inhibited that depletion.
|
30802989 |
2019 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The correlation between patatin-like phospholipase domain-containing protein 3 (<i>PNPLA3</i>) rs738409 polymorphism and hepatocellular carcinoma was investigated by several pilot studies, but the results of these studies were controversial.
|
30852978 |
2019 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We compared distributions of PNPLA3 genotypes in 80 and 81 Caucasian patients with alcoholic and hepatitis C virus (HCV)-associated HCC to 80 and 81 age- and sex-matched patients with alcohol-related and HCV-related cirrhosis without HCC, respectively.
|
22087248 |
2011 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Next, we will analyze the evidences for the association between PNPLA3 I148M variant and HCC.
|
23333103 |
2013 |